Press Releases July 15, 2026 08:05 AM

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

BillionToOne to announce Q2 2026 earnings on August 5, 2026 with a scheduled earnings call

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
BLLN

BillionToOne, a molecular diagnostics company specializing in accurate DNA molecule counting, plans to release its financial results for Q2 2026 after market close on August 5, 2026. The company will host a conference call and webcast to discuss the results the same day.

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
BLLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BillionToOne is reporting its Q2 2026 financial results on August 5, 2026 after market close.
  • The company specializes in molecular diagnostics using its patented Quantitative Counting Templates (QCT) technology that counts DNA molecules at the single-molecule level.
  • A live webcast and analyst conference call are planned to discuss the results and company updates.

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Investor Contact
[email protected]

Media Contact
[email protected]


Risks

  • The article does not disclose financial performance details, creating uncertainty around the upcoming results which could impact the stock price.
  • The molecular diagnostics industry is competitive and dependent on technological innovation, which may pose execution risks for BillionToOne.
  • Market reaction can be influenced by how results compare to analyst expectations and broader healthcare sector trends.

More from Press Releases

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 Aug 29, 2026 Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Aug 29, 2026 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity Aug 28, 2026 Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update Aug 28, 2026 AiRWA receives expected notification of deficiency from Nasdaq related to delayed filing of annual report on Form 10-K Aug 28, 2026